Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Declines By 50.9%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the target of a large decrease in short interest during the month of February. As of February 28th, there was short interest totalling 5,400 shares, a decrease of 50.9% from the February 13th total of 11,000 shares. Based on an average daily trading volume, of 9,900 shares, the days-to-cover ratio is currently 0.5 days.

Santen Pharmaceutical Stock Down 1.4 %

Shares of SNPHY stock traded down $0.14 on Friday, reaching $9.53. The company had a trading volume of 747 shares, compared to its average volume of 11,155. The business’s 50-day moving average is $9.66 and its 200 day moving average is $10.88. Santen Pharmaceutical has a one year low of $8.65 and a one year high of $13.00.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.